Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously

Next Previous
Trial Profile

Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obexelimab (Primary) ; Obexelimab (Primary)
  • Indications Autoimmune disorders; Immunoglobulin G4-related disease; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Xencor

Most Recent Events

  • 15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
  • 14 Nov 2022 Results assessing the pharmacokinetics (PK), receptor occupancy (RO), and pharmacodynamics (PD) of obexelimab following intravenous (IV) administration in adult healthy volunteers and in patients with rheumatoid arthritis presented at the ACR Convergence 2022
  • 09 May 2017 Results published in a Xencor media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top